KQB168 for advanced solid tumors post immunotherapy
Treatments studied
Part of Cancer clinical trials.
This trial tests a new oral drug (KQB168) given alone or with other medicines for people with advanced solid tumors that have not responded to immunotherapy. The goal is to see if it is safe and can help shrink or slow the growth of cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor cancer that has been confirmed by a biopsy.
- Your cancer has grown or spread after you were treated with immunotherapy.
- There are no other treatments available that can cure your cancer.
- Your organs (like liver, kidneys, and bone marrow) are working well enough.
- You have at least one tumor that can be measured on scans.
- You do not have any active tumors in your brain, serious lung or heart problems, or an uncontrolled autoimmune condition.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called KQB365, alone or with other drugs, for people with advanced solid tumors that have a specific KRAS mutation (G12C or G12S). It aims to see if the treatment is safe and effective.
This trial tests a new drug called KQB548 for people with certain advanced cancers (pancreatic, colorectal, or lung) that have a specific genetic change called KRAS G12D. It's for those whose cancer has continued to grow despite previous treatments.
This study tests a new drug called KQB368 for advanced solid cancers that have a specific genetic change (KRAS G12C or G12S mutation). The drug is designed to target this mutation and may help slow or shrink tumors in patients who don't have other curative treatment options.
This trial tests an experimental tablet called TQB3217 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and helps shrink or control the tumor.
This trial is testing a new oral medication called TQB3107 for people with advanced solid tumors (cancer that has spread or cannot be removed). The study aims to see if the drug is safe and how well it works.
This trial tests a new drug called TQB6426 for people with advanced solid tumors that have not responded to other treatments. The drug targets a protein called GPC3 found on some tumors, aiming to deliver a powerful therapy directly to the cancer cells.
Hear when a new Solid Tumor Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.